Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $136.00 at Morgan Stanley

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective reduced by Morgan Stanley from $150.00 to $136.00 in a report published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

RYTM has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd. Telsey Advisory Group set a $143.00 target price on shares of Rhythm Pharmaceuticals in a report on Thursday, March 12th. Citigroup reissued an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Friday, December 12th. Guggenheim boosted their price target on Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Citizens Jmp upped their price target on Rhythm Pharmaceuticals from $167.00 to $176.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.75.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM opened at $87.68 on Tuesday. Rhythm Pharmaceuticals has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The firm has a market cap of $5.99 billion, a PE ratio of -28.19 and a beta of 2.06. The business has a 50 day moving average price of $99.77 and a 200-day moving average price of $102.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. During the same period in the previous year, the firm earned ($0.72) earnings per share. The firm’s revenue for the quarter was up 36.9% on a year-over-year basis. Research analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Buying and Selling

In related news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer owned 110,512 shares in the company, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Christopher Paul German sold 5,614 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer owned 160 shares of the company’s stock, valued at $14,329.60. The trade was a 97.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 27,267 shares of company stock worth $2,719,955. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RYTM. RA Capital Management L.P. increased its stake in Rhythm Pharmaceuticals by 17.3% during the 4th quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock valued at $713,618,000 after purchasing an additional 985,478 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Rhythm Pharmaceuticals by 24.3% during the fourth quarter. Vanguard Group Inc. now owns 6,210,916 shares of the company’s stock valued at $664,816,000 after buying an additional 1,214,489 shares during the last quarter. State Street Corp increased its position in shares of Rhythm Pharmaceuticals by 8.4% during the fourth quarter. State Street Corp now owns 2,198,615 shares of the company’s stock valued at $235,340,000 after acquiring an additional 169,964 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Rhythm Pharmaceuticals by 2.5% during the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock valued at $174,499,000 after acquiring an additional 41,391 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in Rhythm Pharmaceuticals by 21.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock worth $102,966,000 after acquiring an additional 288,376 shares during the last quarter.

Key Headlines Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company delivered solid revenue growth and a Q4 beat (FY25 revenue $194.8M, +50% year/year), which supports continued commercial demand for IMCIVREE (setmelanotide) and underpins longer-term upside. Article Title
• Positive Sentiment: Company highlights post‑hoc analyses showing statistically significant BMI reductions at 52 weeks in patients with heterozygous POMC/PCSK1 and SRC1 (NCOA1) variants — these subgroup signals could support label expansion or targeted use, which investors may view as constructive if regulators/market accept the evidence. Article Title
• Neutral Sentiment: Company-hosted transcript and slide materials on the EMANATE topline results are available for investors evaluating the detailed data and management commentary; these provide context for both the misses and the subgroup findings. Transcript Slides
• Negative Sentiment: Topline EMANATE results showed the experimental obesity program did not meet several pre‑specified primary endpoints across four substudies — the primary failure is the main driver of near‑term negative sentiment and regulatory scrutiny. Reuters
• Negative Sentiment: Multiple major brokerages trimmed price targets today (Citigroup, RBC, Citizens JMP, BofA, Morgan Stanley, Needham). Although most retained buy/outperform ratings, the lower targets signal reduced near‑term upside expectations and likely contributed to selling pressure. Benzinga TickerReport

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.